Discovery of the cysteine dynamics during the development and treatment of diabetic process by fluorescent imaging
Kai Wang,
Kun Yao,
Xu-Yang Chen,
Da-Ke Wen,
Ya-Juan Qin,
Zhi-Gang Hu,
Yu-Shun Yang
Affiliations
Kai Wang
Department of Medical Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi, Jiangsu, China; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, China
Kun Yao
School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China; Laboratory of Medicinal Chemical Biology, Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China
Xu-Yang Chen
Department of Medical Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi, Jiangsu, China; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, China
Da-Ke Wen
Department of Medical Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi, Jiangsu, China
Ya-Juan Qin
School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China
Zhi-Gang Hu
Department of Medical Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi, Jiangsu, China; Corresponding author.
Yu-Shun Yang
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, China; Jinhua Advanced Research Institute, Jinhua, 321019, China; Corresponding author. State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Jinhua Advanced Research Institute, Nanjing, 210023, China.
Herein, a novel fluorescent probe RhoDCM was developed for monitoring the cysteine (Cys) dynamics. For the first time, the Cys-triggered implement was applied in relatively complete diabetic mice models. The response of RhoDCM towards Cys suggested advantages including practical sensitivity, high selectivity, rapid reaction, and steadiness in various pH and temperature conditions. RhoDCM could basically monitor the intracellular Cys level, both exogenous and endogenous. It could further monitor the glucose level via detecting consumed Cys. Furthermore, the diabetic mice models including the no diabetic control group, the induced model groups by streptozocin (STZ) or alloxan, and the treatment groups induced by STZ and treated with vildagliptin (Vil), dapagliflozin (DA), or metformin (Metf) were constructed. The models were checked by oral glucose tolerance test and significant liver-related serum indexes. Based on the models, the in vivo imaging and penetrating depth fluorescence imaging both indicated that RhoDCM could characterize the status of the development and treatment in the diabetic process via monitoring the Cys dynamics. Consequently, RhoDCM seemed beneficial for inferring the order of severity in the diabetic process and evaluating the potency of therapeutic schedules, which might be informatic for correlated investigations.
